Effect on Left Ventricular Systolic Function after 3 Months of SGLT2 Inhibitor Therapy in Heart Failure with Reduced Ejection Fraction patients
Dr. Mayank Sharma
MBBS, MD (Medicine),
Consultant Internal Medicine – Indus International Hospital, Mohali.
The impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on echocardiographic measurements of left ventricular (LV) systolic function in patients with heart failure and reduced ejection fraction (HFrEF) is not well understood. 59 outpatients with HFrEF were enlisted; 18 patients underwent OMT alone (SGLT2i group), whereas 41 patients received SGLT2i plus OMT (SGLT2i+ group). 3D ejection fraction (3D LVEF), Myocardial work index (MWI), and global longitudinal strain (GLS) were measured at baseline and after 3 months after treatment. The SGLT2i+ group considerably outperformed the SGLT2i group in terms of MWI improvement at the 3-month follow-up. Both groups saw a considerable improvement in their 3D LVEF and LV GLS, circulating NT-proBNP levels, and NYHA functional class; however, the SGLT2i+ group experienced a much higher improvement. In conclusion, LV systolic function among outpatients with HFrEF improved more when SGLT2i was added to completely optimised background medical treatment.
Click Here to view the article: